Tuberc Respir Dis.  2023 Jul;86(3):151-157. 10.4046/trd.2022.0147.

Inhaled Corticosteroids Is Not Associated with the Risk of Pneumonia in Asthma

• Lee YJ
• Park YB

• KMID: 2543169
• DOI: http://doi.org/10.4046/trd.2022.0147

Abstract

The introduction of inhaled corticosteroids (ICS) for the management of asthma has led to a decrease in acute exacerbation of asthma. However, there are concerns regarding the safety of long-term ICS use, particularly pneumonia. Growing evidence indicates that ICS use is associated with an increased risk of pneumonia in patients with chronic obstructive pulmonary disease, whereas the risk in patients with asthma remains unclear. This review discusses the effect of ICS on pneumonia among patients with asthma to update the existing literature. Asthma is associated with an increased risk of pneumonia. Several hypotheses have been proposed to explain this association, including that asthma impairs the clearance of bacteria owing to chronic inflammation. Therefore, controlling airway inflammation with ICS may prevent the occurrence of pneumonia in asthma. In addition, two meta-analyses investigating randomized control trials showed that ICS use was associated with a protective effect against pneumonia in asthma.

Keyword

Inhaled Corticosteroids; Asthma; Pneumonia